Yes, YK11 does decrease myostatin. It is often described as a myostatin inhibitor.
However, its mechanism is indirect and unique. Instead of binding to myostatin directly, YK11 works by upregulating the expression of follistatin (Fst). Follistatin is a natural protein that acts as a potent antagonist and inhibitor of myostatin.
Here is a summary of the key points from the research:
| Mechanism | Description |
|---|---|
| Indirect Inhibition | YK11 decreases myostatin by increasing the production of its natural inhibitor, follistatin. |
| Unique Pathway | This follistatin-inducing effect is unique to YK11 and is not observed with other similar compounds like DHT, RAD140, or LGD-4033. |
| Critical Role of Follistatin | The muscle-building effects of YK11 are significantly reduced when follistatin is neutralized, proving this indirect pathway is essential for its function. |
References:
●YK11 serves as an Androgen Receptor (AR) agonist that stimulates muscle growth while inhibiting myostatin.
●The myostatin inhibitor, YK-11, blocks myostatin by upregulating its antagonist, follistatin.
●YK11 treatment of C2C12 cells, but not DHT, induced the expression of follistatin (Fst).
●YK11 uniquely induces follistatin expression, thereby indirectly suppressing myostatin, a pathway inaccessible to standard SARM candidates.
https://www.hormonerawsource.com/sarm-powders/sarms-finished/high-quality-stromusc-yk11-10mg-for.html
